CA2577046A1 - Chemokine combinations to mobilize progenitor/stem cells - Google Patents

Chemokine combinations to mobilize progenitor/stem cells Download PDF

Info

Publication number
CA2577046A1
CA2577046A1 CA002577046A CA2577046A CA2577046A1 CA 2577046 A1 CA2577046 A1 CA 2577046A1 CA 002577046 A CA002577046 A CA 002577046A CA 2577046 A CA2577046 A CA 2577046A CA 2577046 A1 CA2577046 A1 CA 2577046A1
Authority
CA
Canada
Prior art keywords
pyridinylmethyl
tetrahydro
methyl
methylene
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002577046A
Other languages
English (en)
French (fr)
Inventor
Gary J. Bridger
Louis M. Pelus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anormed Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2577046A1 publication Critical patent/CA2577046A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/195Chemokines, e.g. RANTES
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CA002577046A 2004-08-13 2005-08-11 Chemokine combinations to mobilize progenitor/stem cells Abandoned CA2577046A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60136704P 2004-08-13 2004-08-13
US60/601,367 2004-08-13
PCT/US2005/028783 WO2006020891A2 (en) 2004-08-13 2005-08-11 Chemokine combinations to mobilize progenitor/stem cells

Publications (1)

Publication Number Publication Date
CA2577046A1 true CA2577046A1 (en) 2006-02-23

Family

ID=35908186

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002577046A Abandoned CA2577046A1 (en) 2004-08-13 2005-08-11 Chemokine combinations to mobilize progenitor/stem cells

Country Status (9)

Country Link
US (1) US20060035829A1 (cg-RX-API-DMAC7.html)
EP (1) EP1796716A4 (cg-RX-API-DMAC7.html)
JP (1) JP2008509928A (cg-RX-API-DMAC7.html)
CN (1) CN101094684A (cg-RX-API-DMAC7.html)
AU (1) AU2005272653A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0514343A (cg-RX-API-DMAC7.html)
CA (1) CA2577046A1 (cg-RX-API-DMAC7.html)
TW (1) TW200608991A (cg-RX-API-DMAC7.html)
WO (1) WO2006020891A2 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435939B2 (en) * 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
CA2619828A1 (en) * 2005-08-19 2007-02-22 Genzyme Corporation Methods to enhance chemotherapy
MX2008010895A (es) * 2006-02-24 2008-09-03 Genzyme Corp Metodos para aumentar el flujo sanguineo y/o promover la regeneracion de tejidos.
JP5257068B2 (ja) 2006-05-16 2013-08-07 小野薬品工業株式会社 保護されていてもよい酸性基を含有する化合物およびその用途
US20090325992A1 (en) 2006-07-31 2009-12-31 Ono Pharmaceutical Co., Ltd. Compound having cyclic group bound thereto through spiro binding and use thereof
US20100003224A1 (en) * 2006-08-02 2010-01-07 Genzyme Corporation Combination Therapy
WO2008075371A2 (en) * 2006-12-21 2008-06-26 Biokine Therapeutics Ltd. T-140 peptide analogs having cxcr4 super-agonist activity for immunomodulation
BRPI1009663A2 (pt) * 2009-06-14 2016-10-11 Biokine Therapeutics Ltd "método para elevação dos níveis plaquetários em um indivíduo com essa necessidade, método de inibição de hemorragia em um indivíduo que a necessite e composição farmacêutica"
JP2014513727A (ja) 2011-05-16 2014-06-05 ジェンザイム・コーポレーション Cxcr4拮抗薬の使用
CN103159690B (zh) * 2011-12-14 2015-03-25 朱靖华 对称大环胺化合物的结晶形式
US9439942B2 (en) 2012-04-24 2016-09-13 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
US11116738B2 (en) 2012-06-07 2021-09-14 Children's Hospital Los Angeles Methods for treating neutropenia using retinoid agonists
US11116819B2 (en) * 2013-02-28 2021-09-14 President And Fellows Of Harvard College Methods and compositions for mobilizing stem cells
WO2015126989A1 (en) 2014-02-18 2015-08-27 Children's Hospital Los Angeles Compositions and methods for treating neutropenia
WO2016191811A1 (en) 2015-06-03 2016-12-08 The University Of Queensland Mobilizing agents and uses therefor
US10682390B2 (en) 2015-07-16 2020-06-16 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
BR112018016924A2 (pt) 2016-02-23 2019-01-02 Biolinerx Ltd método de seleção de regime de tratamento para indivíduo que tem leucemia mieloide aguda (lma), método de maximização de resposta ao tratamento de leucemia mieloide aguda (lma), método de tratamento de lma, antagonista de cxcr4 e agente quimioterápico no tratamento de lma
JP2019507596A (ja) * 2016-02-26 2019-03-22 プレジデント アンド フェローズ オブ ハーバード カレッジ 生着性の高い造血幹細胞
WO2018085574A2 (en) * 2016-11-02 2018-05-11 Washington University Compositions comprising an integrin inhibitor and agents which interact with a chemokine and methods of use thereof
TW201841916A (zh) 2017-04-12 2018-12-01 美商麥珍塔治療學股份有限公司 芳香烴受體拮抗劑及其用途
WO2019089833A1 (en) 2017-10-31 2019-05-09 Magenta Therapeutics Inc. Compositions and methods for hematopoietic stem and progenitor cell transplant therapy
EP3704232A1 (en) 2017-10-31 2020-09-09 Magenta Therapeutics, Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells
AU2018378804B2 (en) * 2017-12-06 2025-10-02 Ensoma, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US10058573B1 (en) * 2017-12-06 2018-08-28 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem cells
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US20200338132A1 (en) 2018-01-03 2020-10-29 Magenta Therapeutics Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders
US20220401481A1 (en) 2019-11-01 2022-12-22 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
WO2021222313A1 (en) 2020-04-27 2021-11-04 Magenta Therapeutics, Inc. Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo
WO2022197776A1 (en) 2021-03-16 2022-09-22 Magenta Therapeutics, Inc. Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients
CN116789639A (zh) * 2022-03-14 2023-09-22 上海医药工业研究院有限公司 Mavorixafor的纯化方法、其盐及有关物质

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680174A (en) * 1984-05-24 1987-07-14 Damon Biotech, Inc. Induction of immune response by immunization with encapsulated antigen-producing cells
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US6001826A (en) * 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
US5021409A (en) * 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
GB9126677D0 (en) * 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
WO1994029341A1 (en) * 1993-06-08 1994-12-22 Smithkline Beecham Corporation Methods of enhancing bioactivity of chemokines
DE4320478B4 (de) * 1993-06-21 2007-11-15 Robert Bosch Gmbh Fahrstabilitätsregler
WO1995016464A1 (en) * 1993-12-14 1995-06-22 Johns Hopkins University School Of Medicine Controlled release of pharmaceutically active substances for immunotherapy
GB9400411D0 (en) * 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
GB9511357D0 (en) * 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US6506770B1 (en) * 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
US6713052B1 (en) * 1995-10-24 2004-03-30 Human Genome Sciences, Inc. Method of mobilizing stem cells with chemokine β-8
EP1016726A1 (en) * 1998-12-30 2000-07-05 Introgene B.V. Gene therapy to promote angiogenesis
US6365583B1 (en) * 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
US6750348B1 (en) * 1999-03-24 2004-06-15 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
ATE428706T1 (de) * 1999-12-17 2009-05-15 Genzyme Corp Chemokinrezeptor-bindende heterocyclische verbindungen
AU2001293551B2 (en) * 2000-09-15 2007-08-23 Anormed Inc. Chemokine receptor binding heterocyclic compounds
HUP0302960A3 (en) * 2000-09-15 2007-03-28 Anormed Inc Chemokine receptor binding heterocyclic compounds, their use and pharmaceutical compositions contining them
CN1457339A (zh) * 2000-09-15 2003-11-19 阿诺麦德股份有限公司 趋化因子受体结合性杂环化合物
BR0114246A (pt) * 2000-09-29 2003-10-07 Anormed Inc Processo para preparação de poliaminas cìclicas contendo n nitrogênios de anel n-1 protegidas e seus produtos
WO2002081727A2 (en) * 2001-04-03 2002-10-17 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
SI1411918T1 (sl) * 2001-07-31 2012-04-30 Genzyme Global S A R L Postopki za mobilizacijo progenitorskih/matičnih celic
WO2003048345A1 (en) * 2001-12-07 2003-06-12 Toolgen, Inc. Phenotypic screen of chimeric proteins
EP1613613B1 (en) * 2003-04-11 2021-06-02 Genzyme Corporation Cxcr4 chemokine receptor binding compounds
US7550484B2 (en) * 2003-04-22 2009-06-23 Genzyme Corporation Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US7491735B2 (en) * 2003-12-11 2009-02-17 Genzyme Corporation Chemokine receptor binding compounds

Also Published As

Publication number Publication date
BRPI0514343A (pt) 2008-06-10
AU2005272653A1 (en) 2006-02-23
US20060035829A1 (en) 2006-02-16
JP2008509928A (ja) 2008-04-03
TW200608991A (en) 2006-03-16
EP1796716A2 (en) 2007-06-20
WO2006020891A3 (en) 2006-07-13
CN101094684A (zh) 2007-12-26
WO2006020891A2 (en) 2006-02-23
EP1796716A4 (en) 2010-09-08

Similar Documents

Publication Publication Date Title
CA2577046A1 (en) Chemokine combinations to mobilize progenitor/stem cells
CA2455559C (en) Methods to mobilize progenitor/stem cells
AU2007281677A1 (en) Combination therapy
US20100003224A1 (en) Combination Therapy
US20050043367A1 (en) Methods to mobilize progenitor/stem cells
AU2002318927A1 (en) Methods to mobilize progenitor/stem cells
EP1991221B1 (en) Methods for increasing blood flow and/or promoting tissue regeneration
MX2007001802A (en) Chemokine combinations to mobilize progenitor/stem cells
HK40026817A (en) Methods to mobilize progenitor/stem cells

Legal Events

Date Code Title Description
FZDE Discontinued